n a lipoprotein that transports cholesterol in the blood; composed of a high proportion of protein and relatively little cholesterol; high levels are thought to be associated with decreased risk of coronary heart disease and atherosclerosis
GeneNews Enters Into Joint Venture to Establish US CLIA Lab TORONTO -- GeneNews Limited announced today that it has formed a joint venture with two private American companies, Health Diagnostic Laboratory, Inc. ("HDL") and a sales organization with national ...
July 2, 2013 - GlobeNewswire via Yahoo! Finance
Magruder Hospital offers health screening PORT CLINTON — Magruder Hospital will offer its monthly cholesterol (total/LDL/HDL/Triglycerides), blood pressure and glucose screening for $16 at 1 p.m. July 11. Appointments can be made by calling 419-734-3131 ext. 3420.
June 30, 2013 - Port Clinton News Herald
More Bad News For HDL Therapies: ASSURE Trial Misses Primary Endpoint The string of bad news for HDL-related therapies continues. Resverlogix yesterday announced that the ASSURE clinical trial had failed to meet its primary endpoint. RVX-208, the drug being studied in the trial, is a novel small molecule that increases production of ApoA-1, which raises HDL levels and is thought to enhance reverse cholesterol transport.
June 28, 2013 - Forbes
Herman Goering in Newswise (press release) Although in this paper we show how we used the method to find a gene with a big influence on HDL cholesterol, we've begun applying this same approach to every disease that we work on and have obtained outstanding results,said Harald Göring,...
Sebastian Thrun in Business Wire (press release) The Velodyne HDL-64E was a major asset in our Junior robot and contributed significantly to our second place finish in this challenging race,said Sebastian Thrun, Professor of Computer Science and Director of the Artificial Intelligence...
Glenn in Chicago Tribune From an Abbott perspective, the torcetrapib discontinuation will eliminate one major competitor from the combination therapy, HDL-raising market,said Glenn Reicin, an analyst with Morgan Stanley in New York.